Patents Assigned to Mati Therapeutics, Inc.
-
Patent number: 11951038Abstract: Lacrimal implants for treating diseases or disorders are disclosed. More particularly, lacrimal implants, methods of making such implants, and methods of treating ocular, respiration, inner ear or other diseases or disorders using such implants are disclosed.Type: GrantFiled: October 7, 2019Date of Patent: April 9, 2024Assignee: Mati Therapeutics Inc.Inventors: Alan R. Rapacki, Valery Rubinchik, John B. Holds, Sylvie Sim, Danny Shen
-
Patent number: 11712370Abstract: Lacrimal implants and related methods providing secure, wedgable retention within a lacrimal punctum and associated canaliculus of an eye are disclosed. The lacrimal implants can comprise an implant body configured for at least partial insertion through the lacrimal punctum and into the canaliculus. The implant body can include first and second portions, and can extend from a proximal end of the first portion defining a longitudinal proximal axis to a distal end of the second portion defining a longitudinal distal axis. The implant body can be configured such that, when implanted using an integral dilator, an angled intersection exists between the proximal and distal axes. In this way, at least a portion of the implant body can be biased against at least a portion of the lacrimal canaliculus located at or more distal to a canalicular curvature, thereby retaining an implanted position of the lacrimal implant using anatomical structures.Type: GrantFiled: March 21, 2019Date of Patent: August 1, 2023Assignee: Mati Therapeutics Inc.Inventors: Alan R. Rapacki, Valery Rubinchik, Charles Richard Kjellbotn
-
Publication number: 20230165791Abstract: An implant for insertion into a punctum of a patient comprises a body. The body has a distal end, a proximal end, and an axis therebetween. The distal end of the body is insertable distally through the punctum into the canalicular lumen. The body comprises a therapeutic agent included within an agent matrix drug core. Exposure of the agent matrix to the tear fluid effects an effective therapeutic agent release into the tear fluid over a sustained period. The body has a sheath disposed over the agent matrix to inhibit release of the agent away from the proximal end. The body also has an outer surface configured to engage luminal wall tissues so as to inhibit expulsion when disposed therein. In specific embodiments, the agent matrix comprises a non-bioabsorbable polymer, for example silicone in a non-homogenous mixture with the agent.Type: ApplicationFiled: August 6, 2022Publication date: June 1, 2023Applicant: Mati Therapeutics Inc.Inventors: Eugene de Juan, JR., Cary Reich, Stephen Boyd, Hanson S. Gifford, III, Mark Deem
-
Patent number: 11633300Abstract: A device for delivering a treatment medium to an eye includes a first body portion configured to be removably inserted and secured in an opening of the eye, and a second body portion supported by the first body portion. At least the second body portion includes a treatment medium, and a coating having an opening through which the treatment medium elutes out of the device.Type: GrantFiled: March 2, 2020Date of Patent: April 25, 2023Assignee: Mati Therapeutics Inc.Inventor: Eliot Lazar
-
Publication number: 20220331160Abstract: An insertion tool, systems, and methods for use with lacrimal implants are herein provided. An insertion tool is disclosed that includes an inserter tip with a static pin at a distal end configured to be placed in a bore of a lacrimal implant and a mechanical coupling to receive a handle at a proximal end of the inserter tip; and, a handle coupled to the inserter tip at a distal end of the handle and a plunger at a proximal end of the handle, wherein the plunger is configured to release the inserter tip from the handle. The static pin of the inserter tip is de-coupled from the lacrimal implant after placement in a lacrimal canaliculus without mechanical force from the insertion tool.Type: ApplicationFiled: June 29, 2022Publication date: October 20, 2022Applicant: Mati Therapeutics Inc.Inventors: Deepank Utkhede, Jon Wallace, Robert Williams
-
Patent number: 11406532Abstract: An insertion tool, systems, and methods for use with lacrimal implants are herein provided. An insertion tool is disclosed that includes an inserter tip with a static pin at a distal end configured to be placed in a bore of a lacrimal implant and a mechanical coupling to receive a handle at a proximal end of the inserter tip; and, a handle coupled to the inserter tip at a distal end of the handle and a plunger at a proximal end of the handle, wherein the plunger is configured to release the inserter tip from the handle. The static pin of the inserter tip is de-coupled from the lacrimal implant after placement in a lacrimal canaliculus without mechanical force from the insertion tool.Type: GrantFiled: July 13, 2017Date of Patent: August 9, 2022Assignee: Mati Therapeutics Inc.Inventors: Deepank Utkhede, Jon Wallace, Robert Williams
-
Patent number: 11406592Abstract: An implant for insertion into a punctum of a patient comprises a body. The body has a distal end, a proximal end, and an axis therebetween. The distal end of the body is insertable distally through the punctum into the canalicular lumen. The body comprises a therapeutic agent included within an agent matrix drug core. Exposure of the agent matrix to the tear fluid effects an effective therapeutic agent release into the tear fluid over a sustained period. The body has a sheath disposed over the agent matrix to inhibit release of the agent away from the proximal end. The body also has an outer surface configured to engage luminal wall tissues so as to inhibit expulsion when disposed therein. In specific embodiments, the agent matrix comprises a non-bioabsorbable polymer, for example silicone in a non-homogenous mixture with the agent.Type: GrantFiled: October 23, 2018Date of Patent: August 9, 2022Assignee: Mati Therapeutics Inc.Inventors: Eugene de Juan, Jr., Cary Reich, Stephen Boyd, Hanson S. Gifford, III, Mark Deem
-
Patent number: 11324693Abstract: A solid matrix sustained release ophthalmic formulation for topical delivery of a solid ophthalmic drug to the eye, medical devices, drug cores, drug inserts and drug delivery systems comprising the formulation, methods of manufacturing the formulation, medical devices and their methods thereof for delivering the ophthalmic drug for a treatment period provided herein. The formulation disclosed herein is an admixture of an ophthalmic drug, and a combination of a hydrophobic polymer, a hydrophilic polymer and a surfactant, wherein the drug is eluted daily over an extended period of time at therapeutic dose of drug.Type: GrantFiled: March 30, 2020Date of Patent: May 10, 2022Assignee: Mati Therapeutics Inc.Inventors: Deepank Utkhede, Catherine Jones, David Wiseman
-
Publication number: 20220031507Abstract: This document discusses, among other things, an apparatus comprising a lacrimal implant insertable at least partially into a lacrimal punctum. The lacrimal implant comprises an implant core, and an implant body. The implant body includes a cavity sized and shaped to receive the implant core. At least one of the implant core and the implant cavity includes a detection device configured to allow automatic detection of the lacrimal implant with a separate detector device.Type: ApplicationFiled: October 12, 2021Publication date: February 3, 2022Applicant: Mati Therapeutics, Inc.Inventors: Eugene de Juan, Stephen Boyd, Cary J. Reich, Christopher V. Cardenas, Tommy Jewell, Lorrie Ma, Tuan Nguyen
-
Patent number: 11141312Abstract: This document discusses, among other things, an apparatus comprising a lacrimal implant insertable at least partially into a lacrimal punctum. The lacrimal implant comprises an implant core, and an implant body. The implant body includes a cavity sized and shaped to receive the implant core. At least one of the implant core and the implant cavity includes a detection device configured to allow automatic detection of the lacrimal implant with a separate detector device.Type: GrantFiled: April 20, 2015Date of Patent: October 12, 2021Assignee: Mati Therapeutics Inc.Inventors: Eugene de Juan, Jr., Stephen Boyd, Cary J. Reich, Christopher V. Cardenas, Tommy Jewell, Lorrie Ma, Tuan Nguyen
-
Publication number: 20210212941Abstract: An implant for insertion through a punctum and into a canalicular lumen of a patient. The implant includes a matrix of material, a therapeutic agent dispersed in the matrix of material, a sheath disposed over a portion of the matrix of material and configured to inhibit the therapeutic agent from being released from the matrix of material into the canalicular lumen and to allow the therapeutic agent to be released from a surface of the matrix of material to a tear film, and a retention structure configured to retain the implant within the canalicular lumen.Type: ApplicationFiled: December 24, 2020Publication date: July 15, 2021Applicant: Mati Therapeutics, Inc.Inventors: Eugene de Juan, Stephen Boyd, Cary J. Reich, Alan R. Rapacki, Hanson S. Gifford, Mark Deem
-
Publication number: 20210023165Abstract: A solid matrix sustained release ophthalmic formulation for topical delivery of the ophthalmic drug cyclosporine to the eye, medical devices, drug cores, drug inserts and drug delivery systems comprising the formulation, methods of manufacturing the formulation, medical devices and their methods thereof for delivering the ophthalmic drug for a treatment period are provided herein.Type: ApplicationFiled: March 29, 2019Publication date: January 28, 2021Applicant: Mati Therapeutics, Inc.Inventors: Deepank Utkhede, David J. Wiseman
-
Publication number: 20210007889Abstract: A device for delivering a treatment medium to an eye includes a first body portion configured to be removably inserted and secured in an opening of the eye, and a second body portion supported by the first body portion. At least the second body portion includes a treatment medium, and a coating having an opening through which the treatment medium elutes out of the device.Type: ApplicationFiled: March 2, 2020Publication date: January 14, 2021Applicant: Mati Therapeutics Inc.Inventor: Eliot Lazar
-
Patent number: 10874606Abstract: An implant for insertion through a punctum and into a canalicular lumen of a patient. The implant includes a matrix of material, a therapeutic agent dispersed in the matrix of material, a sheath disposed over a portion of the matrix of material and configured to inhibit the therapeutic agent from being released from the matrix of material into the canalicular lumen and to allow the therapeutic agent to be released from a surface of the matrix of material to a tear film, and a retention structure configured to retain the implant within the canalicular lumen.Type: GrantFiled: August 19, 2019Date of Patent: December 29, 2020Assignee: Mati Therapeutics Inc.Inventors: Eugene de Juan, Jr., Stephen Boyd, Cary Reich, Alan Rapacki, Hanson S. Gifford, Mark Deem
-
Publication number: 20200323685Abstract: A method of decreasing intraocular pressure (IOP) in an eye of a patient in need thereof includes implanting a first lacrimal implant through a firsts punctum and into a first lacrimal canaliculus of the eye of the patient. The method may further comprise implanting a second lacrimal implant through a second punctum and into a second lacrimal canaliculus of the eye of the patient, and releasing, on a sustained basis a therapeutically effective amount of an intraocular pressure-reducing therapeutic agent.Type: ApplicationFiled: April 27, 2020Publication date: October 15, 2020Applicant: Mati Therapeutics, Inc.Inventors: Suzanne Cadden, Yong Hao, Deepank Utkhede, Valery Rubinchik, Charles Richard Kjelbotn
-
Publication number: 20200222317Abstract: A solid matrix sustained release ophthalmic formulation for topical delivery of a solid ophthalmic drug to the eye, medical devices, drug cores, drug inserts and drug delivery systems comprising the formulation, methods of manufacturing the formulation, medical devices and their methods thereof for delivering the ophthalmic drug for a treatment period provided herein. The formulation disclosed herein is an admixture of an ophthalmic drug, and a combination of a hydrophobic polymer, a hydrophilic polymer and a surfactant, wherein the drug is eluted daily over an extended period of time at therapeutic dose of drug.Type: ApplicationFiled: March 30, 2020Publication date: July 16, 2020Applicant: MATI THERAPEUTICS INC.Inventors: Deepank UTKHEDE, Catherine JONES, David WISEMAN
-
Publication number: 20200138701Abstract: A method and apparatus for administering an active agent such as a medicine to a subject, uses an ocular implant such as a punctal plug, to which the active agent has been applied. The implant is installed at the eye of the subject for administering the active agent via tissues of the eye.Type: ApplicationFiled: March 21, 2019Publication date: May 7, 2020Applicant: Mati Therapeutics Inc.Inventors: Steven A. Odrich, Liane C. Glazer
-
Patent number: 10632012Abstract: A method of decreasing intraocular pressure (IOP) in an eye of a patient in need thereof includes implanting a first lacrimal implant through a firsts punctum and into a first lacrimal canaliculus of the eye of the patient. The method may further comprise implanting a second lacrimal implant through a second punctum and into a second lacrimal canaliculus of the eye of the patient, and releasing, on a sustained basis a therapeutically effective amount of an intraocular pressure-reducing therapeutic agent.Type: GrantFiled: April 3, 2017Date of Patent: April 28, 2020Assignee: Mati Therapeutics Inc.Inventors: Suzanne Cadden, Yong Hao, Deepank Utkhede, Valery Rubinchik, Charles Richard Kjelbotn
-
Patent number: 10610407Abstract: A device for delivering a treatment medium to an eye includes a first body portion configured to be removably inserted and secured in an opening of the eye, and a second body portion supported by the first body portion. At least the second body portion includes a treatment medium, and a coating having an opening through which the treatment medium elutes out of the device.Type: GrantFiled: November 20, 2017Date of Patent: April 7, 2020Assignee: Mati Therapeutics Inc.Inventor: Eliot Lazar
-
Patent number: 10603274Abstract: A solid matrix sustained release ophthalmic formulation for topical delivery of a solid ophthalmic drug to the eye, medical devices, drug cores, drug inserts and drug delivery systems comprising the formulation, methods of manufacturing the formulation, medical devices and their methods thereof for delivering the ophthalmic drug for a treatment period provided herein. The formulation disclosed herein is an admixture of an ophthalmic drug, and a combination of a hydrophobic polymer, a hydrophilic polymer and a surfactant, wherein the drug is eluted daily over an extended period of time at therapeutic dose of drug.Type: GrantFiled: October 2, 2017Date of Patent: March 31, 2020Assignee: Mati Therapeutics Inc.Inventors: Deepank Utkhede, Catherine Jones, David Wiseman